Stay updated on Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Sign up to get notified when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.

Latest updates to the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page
- Check7 days agoChange DetectedThe deletions remove sponsor attribution blocks for the study (H. Lee Moffitt Cancer Center and Research Institute) and the reference to the Moffitt Clinical Trials website, as well as the 'Helpful Links Provided by' label. This changes how attribution and related navigation are presented on the page.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now shows Revision: v3.5.4, replacing the previous v3.5.3 label. This indicates a backend/template update to the study record display without changing substantive study details.SummaryDifference0.1%

- Check28 days agoNo Change Detected
- Check43 days agoChange DetectedThe page’s footer “Revision” version was updated from v3.5.2 to v3.5.3, reflecting a backend/site release rather than a change to the study record content.SummaryDifference0.1%

- Check50 days agoChange DetectedRevision: v3.5.2 updated from v3.5.0. No visible changes to study details or page content.SummaryDifference0.1%

- Check64 days agoChange DetectedAdded the keyword/MeSH term 'B-cell chronic lymphocytic leukemia.' Added a new resource link to the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check79 days agoChange DetectedRevision tag updated to v3.5.0, replacing v3.4.3. This is a UI/version change and does not alter study details or eligibility.SummaryDifference0.1%

Stay in the know with updates to Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ibrutinib & PD-1 Blockade in High Risk CLL Clinical Trial page.